Uterine fibroids are common benign tumors that affect between 70% and 80% [1] of women during their lifetime.
These growths represent a significant public health challenge because they are often under-researched and under-funded compared to other major health crises. The disparity in federal research funding is particularly stark when compared to the resources allocated for prostate or breast cancer research [1].
Fibroids are the most common tumor affecting women [2]. They grow on or within the uterine wall and are typically non-cancerous, though some rare cases may become cancerous [2]. Despite their benign nature, these tumors can grow to the size of a grapefruit, or a watermelon [1].
Medical professionals note that the condition is frequently misunderstood. Dr. Daniel Bond said, "A uterine fibroid, while common, is often misunderstood" [3].
While the condition affects women broadly, Black women in the U.S. experience the highest burden of the disease [1]. Systemic health disparities contribute to this higher impact, leaving many women to manage severe symptoms with limited treatment options [1].
Awareness efforts typically peak during July, which is recognized as Fibroid Awareness Month [4]. These campaigns aim to highlight the "silent" symptoms that often lead to delayed diagnosis and treatment.
Because the tumors are not always cancerous, they may not receive the same urgency in clinical or legislative settings. However, the physical havoc they wreak on the body is significant regardless of their malignancy status [1].
“Uterine fibroids affect between 70% and 80% of women during their lifetime.”
The gap between the prevalence of uterine fibroids and the level of federal funding suggests a systemic undervaluation of women's reproductive health, particularly for Black women. When a condition is labeled as 'benign,' it often loses priority in research pipelines, despite the fact that the physical morbidity and quality-of-life impact can be as severe as that of malignant tumors.
